Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
12 times rockets and spacecraft crashed and burned in 2025- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- 7 Heavenly Espressos, One Do You Like?
- Some super-smart dogs can pick up new words just by eavesdropping
- China's Normal Ponders: A Visual Excursion
- 5 things for parents to know about changes to kids vaccine schedule
- The Force of Positive Reasoning: Day to day Attestations
- Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- How one man's concern saved his brothers from heart disease
